Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease.

Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease.

PLoS One. 2017;12(4):e0175929

Authors: Chang WH, Niu DM, Lu CY, Lin SY, Liu TC, Chang JG

Abstract
While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future.

PMID: 28430823 [PubMed - in process]

http://ift.tt/2oeWTJJ